Published in Int J Cancer on July 15, 2007
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells (2008) 3.12
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Biology of angiogenesis and invasion in glioma. Neurotherapeutics (2009) 1.61
Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50
Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol (2008) 1.48
Decorin: a guardian from the matrix. Am J Pathol (2012) 1.46
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res (2013) 1.35
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol (2012) 1.30
Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci (2012) 1.23
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 1.08
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol (2010) 1.01
c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol (2009) 1.01
Tumor-associated macrophages in glioma: friend or foe? J Oncol (2013) 1.00
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res (2013) 0.92
HGF-induced PKCζ activation increases functional CXCR4 expression in human breast cancer cells. PLoS One (2012) 0.89
Imaging hypoxia in gliomas. Br J Radiol (2011) 0.87
Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int (2010) 0.82
Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metastasis (2013) 0.81
Exploring the competition between proliferative and invasive cancer phenotypes in a continuous spatial model. PLoS One (2014) 0.79
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Oncotarget (2015) 0.79
Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. Oncotarget (2015) 0.78
Cancer: a profit-driven biosystem? Med Hypotheses (2008) 0.78
Pathophysiological mechanisms of death resistance in colorectal carcinoma. World J Gastroenterol (2015) 0.78
Glioblastoma: Defining Tumor Niches. Trends Cancer (2015) 0.78
Phenotypic Transition as a Survival Strategy of Glioma. Neurol Med Chir (Tokyo) (2016) 0.78
Elevated cell invasion in a tumor sphere culture of RSV-M mouse glioma cells. Neurol Med Chir (Tokyo) (2014) 0.77
Silencing HIF-1α reduces the adhesion and secretion functions of acute leukemia hBMSCs. Braz J Med Biol Res (2012) 0.77
Hypoxia regulates reactive oxygen species levels in SHG-44 glioma cells. Neural Regen Res (2013) 0.76
Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal‑regulated kinase signaling pathway. Mol Med Rep (2015) 0.75
Adaptation to antiangiogenic therapy in neurological tumors. Cell Mol Life Sci (2015) 0.75
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther (2016) 0.75
The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits. PLoS One (2017) 0.75
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer (2017) 0.75
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Sci Rep (2017) 0.75
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res (2006) 2.48
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology (2013) 1.98
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res (2003) 1.82
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol (2002) 1.74
The impact of esophagus retraction on early dysphagia after anterior cervical surgery: does a correlation exist? Spine (Phila Pa 1976) (2007) 1.74
Lumbar spinal stenosis: prognostic factors for bilateral microsurgical decompression using a unilateral approach. Neurosurgery (2009) 1.68
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer (2012) 1.67
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci (2011) 1.66
Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg (2010) 1.65
RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther (2006) 1.65
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer (2011) 1.61
Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) (2015) 1.51
Consensus document on European brain research. Eur J Neurosci (2011) 1.45
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol (2009) 1.43
Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery (2003) 1.40
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) (2011) 1.39
Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. Arterioscler Thromb Vasc Biol (2010) 1.35
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell (2011) 1.27
Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol (2003) 1.26
Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res (2008) 1.24
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 1.23
Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res (2005) 1.23
Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging. Radiology (2006) 1.22
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19
A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene (2003) 1.19
Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol (2007) 1.18
Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res (2013) 1.17
Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol (2004) 1.17
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol (2015) 1.16
The translaminar approach to lumbar disc herniations impinging the exiting root. Neurosurgery (2008) 1.14
Neural stem cell migration toward gliomas in vitro. Neuro Oncol (2005) 1.10
Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res (2012) 1.10
RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem (2006) 1.07
Novel mutations and repeated findings of mutations in familial Alzheimer disease. Neurogenetics (2005) 1.07
Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia (2012) 1.07
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro Oncol (2013) 1.05
Identification of the adult human hemangioblast. Stem Cells Dev (2004) 1.04
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res (2007) 1.03
Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Res (2009) 1.03
Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res (2004) 1.00
Blister-like aneurysms--a diagnostic and therapeutic challenge. Neurosurg Rev (2011) 1.00
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia (2009) 0.97
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol (2015) 0.97
Epidural hematoma after spinal anesthesia in a patient with undiagnosed epidural lymphoma. Anesth Analg (2004) 0.97
Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res (2004) 0.97
Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest (2013) 0.96
Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta Neuropathol (2013) 0.96
Gene expression profiling of hypothalamic hamartomas: a search for genes associated with central precocious puberty. Horm Res (2007) 0.95
The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev (2012) 0.95
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer (2014) 0.95
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol (2003) 0.94
Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res (2003) 0.94
Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther (2014) 0.94
Autophagic cell death induced by TrkA receptor activation in human glioblastoma cells. J Neurochem (2007) 0.93
RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem (2009) 0.93
HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol (2012) 0.92
Activity parameters of subthalamic nucleus neurons selectively predict motor symptom severity in Parkinson's disease. J Neurosci (2014) 0.92
Terson syndrome in subarachnoid hemorrhage, intracerebral hemorrhage, and traumatic brain injury. Neurosurg Rev (2014) 0.91
Contactin is expressed in human astrocytic gliomas and mediates repulsive effects. Glia (2006) 0.91